Initial experience and validation of a novel tool to assess patient experience in the catheterization laboratory (PATCATH), in patients undergoing coronary angiography or angioplasty

Funding Acknowledgements

Type of funding sources: None.

Background

Patient-reported experience metric (PREM) questionnaires are an important tool for evaluating patient experience.

Purpose

Validated PREM tools may help to identify areas of quality improvement within healthcare.

Methods

A novel tool developed by the Patient Initiative Committee of the European Association of Percutaneous Intervention (EAPCI), in association with the European Society of Cardiology Patient Forum was designed to capture patient experience in the catherization laboratory. The questionnaire is divided into 3 domains assessing experience before, during and after coronary angiography or angioplasty (Figure 1, Panels A-C). Responses were recorded on a scale of strongly agree, agree, disagree, or strongly disagree. Consecutive patients undergoing a coronary angiography or angioplasty received the questionnaire to complete anonymously during recovery following catheterization.

Results

A total of 100 valid responses were received over a four week pilot experience. Most patients had an angiogram procedure (80%). A total of 52% were grouped in the higher age category (≥66 years) (Table 1). Patient response indicated a high level of satisfaction with the experience before the procedure: 98.6% of patients strongly agreed or agreed with statements assessing positive experience reflecting a level of knowledge of why the procedure was recommended and perceived level of support (Figure 1, Panel A). 98.5% strongly agreed or agreed with statements assessing positive experience of comfort, safety, communication and understanding during the procedure (Figure 1, Panel B). A total of 9.6% of patients within the higher age category provided no response regarding their understanding for why a treatment decision was made, whilst all patients in the lower age category responded. After the procedure, 59.3% strongly agreed or agreed with statements assessing positive experience: with lower levels of positive experience for questions related to lifestyle changes (60%), comprehension of a rehabilitation program (46%), medication prescription (58%) and treatment duration (53%) (Figure 1, Panel C). However, 15.2% of questions in this domain had no response, particularly those related to prescribed medication. A lower positive experience was observed between higher versus lower age categories respectively (44.2% & 77.1%) regarding an understanding of necessary lifestyle changes.

Conclusion

The results of our initial experience with a novel PREMs tool highlight high levels of positive experience before and after diagnostic angiography and a lower level of positive experience in the period after the procedure. Completing this tool at a later stage or post-hospital discharge (i.e., following additional education interventions) may help to capture a higher positive response related to after the intervention. To validate these findings, this PREM tool should be evaluated further in additional patient cohorts across multiple sites.

Vasoconstriction to endothelin-1 is blunted in non-insulin-dependent diabetes: a dose-response study

The haemodynamic hypothesis for the pathogenesis of diabetic microangiopathy argues that an initial increase in microvascular blood flow leads to microvascular sclerosis and disturbed autoregulation. Endothelin-1 (ET-1) is an endothelium-derived vasoconstrictor peptide that contributes to basal vascular tone. Impairment of the vasoconstrictor response to ET-1 could result in hyperperfusion and subsequent microvascular damage. The purpose of this study was to determine whether vascular responses to ET-1 are impaired in patients with non-insulin-dependent diabetes mellitus (type 2 diabetes). Ten patients with type 2 diabetes and nine control subjects underwent brachial artery cannulation. Forearm blood flow was measured using strain-gauge venous occlusion plethysmography. ET-1 in three doses of 5, 10, and 20 pmol/min and 0.9% saline placebo was infused in a balanced double-blind randomised manner. Vascular smooth muscle function also was assessed using sodium nitroprusside. Control subjects showed vasoconstriction to ET-1 of 5 (p < 0.05), 10 (p < 0.05), and 20 pmol/min (p < 0.01). In the diabetic group, there was no significant response to ET-1 at 5 pmol/min (p > 0.05); however, significant vasoconstriction developed at 10 and 20 pmol/min (p < 0.01). There was a significant difference in response to ET-1 at 5 pmol/min between the diabetic and control groups (p < 0.05). Responses to sodium nitroprusside were similar in both groups (p > 0.05). Patients with type 2 diabetes have a blunted vasoconstrictor response to ET-1 despite preserved vascular smooth muscle function.

Epidemiology and treatment of left ventricular hypertrophy in the elderly

Left ventricular hypertrophy (LVH) is an important independent risk factor for cardiovascular disease and is associated with an increased risk of ventricular dysrhythmia, coronary artery disease, myocardial infarction, stroke, heart failure and peripheral artery disease. The prevalence of LVH increases strongly with advancing age and, consequently, the prevention or reduction of LVH should be an important consideration in the older age-group. This review summarises current knowledge on LVH and discusses management issues with particular reference to the elderly. Evidence suggests that antihypertensive treatment can reverse or prevent LVH. There have been few studies of LVH in the elderly, but since age does not appear to be a factor in the regression of LVH, results of studies among younger hypertensive patients can be extrapolated to the elderly population. Meta-analyses of clinical studies have not established conclusively that angiotensin-converting enzyme inhibitors and calcium antagonists are necessarily more effective than diuretics and beta-adrenoceptor antagonists in reducing LVH.

Forearm endothelium-dependent vascular responses and the potassium-ATP channel

AIMS

Vasodilation to acetylcholine is mediated at least in part by endothelium-derived hyperpolarising factor (EDHF) which causes membrane hyperpolarisation by activating potassium channels. It is however uncertain which potassium channel mediates this effect. The aim of this study was to determine the role of the potassium-ATP (K(+)-ATP) channel in mediating endothelium-dependent vascular responses to acetylcholine.

METHODS

In 10 healthy volunteers acetylcholine, an endothelium-dependent vasodilator, and sodium nitroprusside as a control assessing endothelium-independent vasodilatation were infused into the non-dominant brachial artery. Forearm blood flow (FBF) in response to each dose was measured by strain-gauge venous occlusion plethysmography. The K(+)-ATP channel blocker glipizide (2.5 mg) was then administered orally. After 45 min the infusions with FBF measurements were repeated.

RESULTS

Acetylcholine (P < 0.01) and sodium nitroprusside (P < 0.01) both caused an increase in FBF. There was no significant difference in vascular responses to acetylcholine (P > 0.05) or sodium nitroprusside (P > 0.05) following K(+)-ATP channel blockade.

CONCLUSIONS

The K(+)-ATP channel does not modulate forearm arteriolar endothelium-dependent responses in healthy volunteers and therefore does not play a role in membrane hyperpolarisation.